← Back to Search

Anti-inflammatory agent

rEV131 for Post-Cataract Surgery Inflammation

Phase 2

Waitlist Available

Research Sponsored by Evolutec Group

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be male or female who has undergone unilateral cataract extraction by phacoemulsification (PHACO) method with implantation of a posterior chamber intraocular lens

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a new anti-inflammatory agent to see if it is safe and effective compared to other treatments for patients with ocular inflammation who have had cataract surgery.

Who is the study for?

This trial is for men and women who have had cataract surgery using the PHACO method with a lens implant. Participants should not have active infections, unstable glaucoma, or be using anti-inflammatory drugs within a week before joining or during the study.Check my eligibility

What is being tested?

The study tests three different strengths of rEV131 against a placebo and an approved anti-inflammatory drug to see how well they reduce eye inflammation after cataract surgery.See study design

What are the potential side effects?

Possible side effects may include irritation at the site of application, increased risk of infection due to immune suppression by anti-inflammatories, and potential impact on other ocular conditions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have had cataract surgery on one eye using PHACO and got a lens implant.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Evolutec GroupLead Sponsor

1 Previous Clinical Trials

112 Total Patients Enrolled

Wynne Weston-Davies, MDStudy DirectorEvolutec Group

Media Library

rEV131 (Anti-inflammatory agent) Clinical Trial Eligibility Overview. Trial Name: NCT00353964 — Phase 2

Conjunctivitis Clinical Trial 2023: rEV131 Highlights & Side Effects. Trial Name: NCT00353964 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this trial have an age limit? If so, what is it?

"The age restriction for this clinical trial is that all participants must be 18 years old or younger."

Answered by AI

Are there any risks associated with this treatment plan?

"Since this is a Phase 2 trial, there is only some data supporting the safety of the treatment. Consequently, our team has rated it as a 2 on our scale."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery

2024. "Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00353964.

All > Cataract